Jeffrey Alan Hawkins Sells 11,311 Shares of Quantum-Si (NASDAQ:QSI) Stock

Quantum-Si Incorporated (NASDAQ:QSI) CEO Jeffrey Alan Hawkins sold 11,311 shares of the business’s stock in a transaction that occurred on Tuesday, June 23rd. The shares were sold at an average price of $0.90, for a total value of $10,179.90. Following the transaction, the chief executive officer directly owned 3,669,802 shares in the company, valued at $3,302,821.80. This trade represents a 0.31% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Jeffrey Alan Hawkins also recently made the following trade(s):

• On Monday, June 22nd, Jeffrey Alan Hawkins sold 11,310 shares of Quantum-Si stock. The stock was sold at an average price of $0.96, for a total value of $10,857.60.
• On Monday, April 20th, Jeffrey Alan Hawkins sold 83,712 shares of Quantum-Si stock. The shares were sold at an average price of $1.01, for a total transaction of $84,549.12.

Quantum-Si Price Performance

NASDAQ:QSI traded down $0.05 during trading hours on Wednesday, hitting $0.83. The company had a trading volume of 5,042,480 shares, compared to its average volume of 6,078,957. The stock has a 50-day moving average price of $0.99 and a 200 day moving average price of $1.04. The company has a market capitalization of $180.13 million, a PE ratio of -1.62 and a beta of 3.18. Quantum-Si Incorporated has a 52 week low of $0.69 and a 52 week high of $3.10.

Quantum-Si (NASDAQ:QSI) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.12) by $0.02. Quantum-Si had a negative net margin of 5,605.88% and a negative return on equity of 47.35%. The business had revenue of $0.26 million during the quarter, compared to analyst estimates of $0.30 million. Analysts anticipate that Quantum-Si Incorporated will post -0.49 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts have weighed in on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Quantum-Si in a research report on Friday, March 27th. Canaccord Genuity Group decreased their target price on Quantum-Si from $1.50 to $1.00 and set a “hold” rating for the company in a research report on Wednesday, March 4th. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Quantum-Si currently has an average rating of “Reduce” and a consensus price target of $1.00.

Institutional Trading of Quantum-Si

A number of hedge funds have recently modified their holdings of the business. Millennium Management LLC bought a new position in shares of Quantum-Si in the 1st quarter worth about $4,721,000. State Street Corp lifted its position in Quantum-Si by 26.5% during the 4th quarter. State Street Corp now owns 3,562,721 shares of the company’s stock valued at $3,919,000 after acquiring an additional 745,231 shares during the period. Squarepoint Ops LLC bought a new stake in Quantum-Si during the third quarter worth about $865,000. Bank of America Corp DE boosted its stake in Quantum-Si by 426.6% during the second quarter. Bank of America Corp DE now owns 465,999 shares of the company’s stock worth $913,000 after acquiring an additional 377,504 shares in the last quarter. Finally, Geode Capital Management LLC grew its holdings in Quantum-Si by 9.8% in the fourth quarter. Geode Capital Management LLC now owns 4,114,375 shares of the company’s stock worth $4,527,000 after purchasing an additional 367,206 shares during the period. Institutional investors own 39.90% of the company’s stock.

Quantum-Si Company Profile

Quantum-Si Inc is a life sciences instrumentation company headquartered in Guilford, Connecticut, developing next-generation proteomics solutions based on semiconductor sequencing technology. The company’s core offering centers on a proprietary single-molecule protein sequencing platform that uses a silicon-based sensor chip to convert protein data into digital signals. This approach is designed to deliver high sensitivity, single-amino-acid resolution and deep proteome coverage while potentially reducing cost and complexity compared to traditional mass spectrometry methods.

Quantum-Si’s product roadmap includes the development and commercialization of an integrated system comprising instruments, consumable reagents and proprietary data analysis software.